ASX RELEASE

Ellex Medical Lasers Limited (ASX:ELX)


Adelaide, Australia

Date: 9 March 2018

Release: Immediate

Topic: Additional Financial Information on Segment Results for the half year ended 31

December 2017



ABOUT ELLEX

Ellex designs, develops, manufactures and sells innovative products that help eye surgeons around the world to effectively and efficiently treat eye disease. Ellex is a world leader in this field. Headquartered in Adelaide, Australia, Ellex has ophthalmic lasers and devices that treat glaucoma, retinal disease primarily caused by diabetes, secondary cataract and vitreous opacities, as well as age-related macular degeneration. Manufacturing is carried out in Adelaide, Australia and Fremont, California. Sales and service directly to eye surgeons is conducted via subsidiary offices in Fremont, Minneapolis, Lyon, Berlin and Tokyo. A network of more than 50 distribution partners around the world services other markets.

For additional information about Ellex and its products, please visit www.ellex.com

For further information on Ellex please contact:

Tom Spurling, CEO
Ellex Medical Lasers Limited
3 Second Avenue, Mawson Lakes, SA, 5095
W +61 8 7074 8293 | M +61 417 818 658
tspurling@ellex.com

Mark Lindh, Investor Relations & Corporate W +61 8 87074 8200 | M +61 414 551 361 mlindh@ellex.com

Maria Maieli, CFO & Company Secretary Ellex Medical Lasers Limited 3 Second Avenue, Mawson Lakes, SA, 5095 W +61 8 7074 8200 mmaieli@ellex.com



Ellex Detailed Profit and Loss by Segment (H1FY18)

	A\$'000's					
	CLU	iTrack	2RT	Corporate	Total	
Revenue	32,825	5,221	197	-	38,243	
Other Income	-	-	-	143	143	
Changes in inventories of finished goods and work in progress	(1,328)	473	(70)	-	(925)	
Raw materials and consumables used	(14,203)	(1,892)	(9)	-	(16,004)	
	17,299	3,802	118			
Gross margin related % ⁽¹⁾	53%	73%	60%			
Employee benefits expense	(9,250)	(3,411)	(55)	(963)	(13,679)	
Depreciation and amortization expense	(1,219)	(476)	(9)	-	(1,704)	
Facilities expense	(928)	(152)	(6)	-	(1,086)	
Legal expenses	-	-	-	(84)	(84)	
Advertising, marketing and congress expense	(1,474)	(749)	(261)	-	(2,484)	
Finance costs	-	-	-	(185)	(185)	
Implied interest for deferred consideration for iTrack acquisition	-	-	-	-	-	
Product development raw materials and consumables used	(449)	-	(3)	-	(452)	
Realised foreign exchange (loss)/gain	(227)	7	(1)	-	(221)	
Other expenses	(1,597)	(1,685)	(206)	(779)	(4,267)	
(Loss)/profit before tax	2,251	(2,664)	(423)	(1,871)	(2,705)	



(1) In accordance with reporting in previous years this ratio is highlighted as a proxy for gross margin as it does not include cost of production labour which is shown in employee benefits

Ellex Detailed Profit and Loss by Segment (H1FY17)

	A\$'000's					
	CLU	iTrack	2RT	Corporate	Total	
Revenue	30,386	3,637	236	-	34,259	
Other Income	-	296	-	383	679	
Changes in inventories of finished goods and work in progress	4,375	(165)	486	-	4,696	
Raw materials and consumables used	(17,370)	(938)	(573)	-	(18,881)	
	17,391	2,534	149			
Gross margin related % ⁽¹⁾	57%	70%	63%			
Employee benefits expense	(8,257)	(1,869)	(64)	(1,139)	(11,329)	
Depreciation and amortization expense	(1,010)	(389)	(7)	-	(1,406)	
Facilities expense	(880)	(80)	(7)	-	(967)	
Legal expenses	-	-	-	(100)	(100)	
Advertising, marketing and congress expense	(1,538)	(158)	(260)	-	(1,956)	
Finance costs	-	-	-	(157)	(157)	
Implied interest for deferred consideration for iTrack acquisition	-	(68)	-	-	(68)	
Product development raw materials and consumables used	(532)	-	(4)	-	(536)	
Realised foreign exchange (loss)/gain	220	(20)	2	-	202	
Other expenses	(2,090)	(156)	(215)	(451)	(2,914)	
(Loss)/profit before tax	3,304	88	(406)	(1,464)	1,522	



(1) In accordance with reporting in previous years this ratio is highlighted as a proxy for gross margin as it does not include cost of production labour which is shown in employee benefits